BioSpace News Archive

Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020. As of June 30, 2020, Odonate had $125.4 million in cash, compared to $180.5 million as of December 31, 2019. Net cash used in operating activities

Transforming the treatment of aortic disorders, Endologix ® Inc. (OTC: ELGXQ) (“Endologix” or the “Company”), today announced the first commercial implant and the U.S. commercial release of its recently FDA-approved ALTO ® endograft for the treatment of abdominal aortic aneurysms (AAA). “ALTO represents a differentiation from traditional endovascular aneurysm repair (EVAR) and, with its introduction, a significant la

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, neuroscience and biodefense announced today that Kineta will be presenting at multiple virtual investor events in August 2020. Shawn Iadonato , Kineta Chief Executive Officer and Craig Philips , President, will present an

Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson , President and Chief Executive Officer, will present at the LifeSci Partners Summer Symposium. The conference takes place virtually on August 5 th . The details of Neurana’s presenta

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively “Noden”) to Stanley Capital (“Stanley Capital”). The total value of the transaction will resul

Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate ®

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza. SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy desig

Neurotrope, Inc. (Nasdaq: NTRP) (“Neurotrope” or the “Company”) today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. (“NBI”), has entered into a services agreement with Worldwide Clinical Trials (“WCT”) to support site recruitment and activation for the Company’s ongoing Phase 2 study of bryostatin-1 in the treatmen

Research Presentation Strategies (RPS), a leader and innovator in the design and technology to support regulatory and pharmaceutical presentations, is pleased to announce it will now be known as SlideSource.